Capstone Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

Capstone Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$440K	Buy	+11,822	New	+$382K	﹤0.01%	1296
2024 Q2	–	Sell	-19,065	Closed	-$800K	–	2139
2024 Q1	$800K	Buy	19,065 +6,412	+51%	+$263K	﹤0.01%	1277
2023 Q4	$502K	Buy	+12,653	New	+$372K	﹤0.01%	1340
2021 Q1	–	Sell	-26,829	Closed	-$470K	–	1703
2020 Q4	$470K	Buy	+26,829	New	+$483K	﹤0.01%	1264

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's CLDX Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 11,822 shares worth $440K. The stake represents ﹤0.01% of the portfolio and ranks #1296 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in CLDX as recently as Q1 2024.

Capstone Investment Advisors first reported a position in CLDX in Q4 2020 and has held it in 4 quarters since. The position peaked at $800K in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Capstone Investment Advisors held 11,822 shares of Celldex Therapeutics worth $440K as of Q2 2026.
Celldex Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1296 holding.
Capstone Investment Advisors first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 4 quarters since.
Capstone Investment Advisors's Celldex Therapeutics position peaked at $800K in Q1 2024.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.